A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NCT ID: NCT00887536

Last Updated: 2022-04-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1613 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-31

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The B-46-I/07132 study, a multicenter, open-label, randomized Phase III, adjuvant therapy trial, will compare the value of adding bevacizumab to a non-anthracycline-based chemotherapy regimen relative to the same chemotherapy without bevacizumab and relative to an anthracycline-based chemotherapy regimen in women with resected node-positive or high-risk node-negative, HER2-negative breast cancer. This trial will determine whether the addition of bevacizumab to a regimen of docetaxel and cyclophosphamide (TCB) improves invasive disease-free survival relative to docetaxel and cyclophosphamide alone (TC). A secondary aim will be to determine whether the addition of bevacizumab to TC improves invasive disease-free survival compared to a regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC). Other secondary aims include whether TCB improves disease-free survival, overall survival, and recurrence-free interval relative to TC alone and to TAC. The toxicities of the three regimens will also be compared.

Patients in the B-46-I/07132 study will be randomized to one of three treatment regimens: Group 1 patients will receive 6 cycles of TAC administered every 21 days (docetaxel 75 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2); Group 2 patients will receive 6 cycles of TC administered every 21 days (docetaxel 75 mg/m2, cyclophosphamide 600 mg/m2); and Group 3 patients will receive 6 cycles of TCB every 21 days with bevacizumab therapy continuing every 21 days after completion of chemotherapy until 1 year following the first dose (docetaxel 75 mg/m2, cyclophosphamide 600 mg/m2, and bevacizumab 15 mg/kg). Primary prophylaxis with pegfilgrastim or filgrastim is required for Group 1 patients (optional for patients in Groups 2 and 3). Patients will also receive adjuvant radiation therapy as clinically indicated and endocrine therapy for hormone receptor-positive tumors.

Tumor samples will be submitted for correlative science studies to evaluate predictors of study therapy benefit. Submission of a tumor sample is a study requirement for all patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: TAC then pegfilgrastim

docetaxel, doxorubicin, cyclophosphamide, and pegfilgrastim/filgrastim

Group Type ACTIVE_COMPARATOR

docetaxel

Intervention Type DRUG

docetaxel 75 mg/m2 IV every 21 days for 6 cycles

doxorubicin

Intervention Type DRUG

doxorubicin 50 mg/m2 IV every 21 days for 6 cycles

cyclophosphamide

Intervention Type DRUG

Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles

Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles

pegfilgrastim

Intervention Type DRUG

pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles \[filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.\]

Group 2: TC

docetaxel and cyclophosphamide

Group Type ACTIVE_COMPARATOR

docetaxel

Intervention Type DRUG

docetaxel 75 mg/m2 IV every 21 days for 6 cycles

cyclophosphamide

Intervention Type DRUG

Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles

Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles

Group 3: TC + bevacizumab

docetaxel, cyclophosphamide, and bevacizumab

Group Type EXPERIMENTAL

bevacizumab

Intervention Type DRUG

bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab

docetaxel

Intervention Type DRUG

docetaxel 75 mg/m2 IV every 21 days for 6 cycles

cyclophosphamide

Intervention Type DRUG

Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles

Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bevacizumab

bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab

Intervention Type DRUG

docetaxel

docetaxel 75 mg/m2 IV every 21 days for 6 cycles

Intervention Type DRUG

doxorubicin

doxorubicin 50 mg/m2 IV every 21 days for 6 cycles

Intervention Type DRUG

cyclophosphamide

Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles

Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles

Intervention Type DRUG

pegfilgrastim

pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles \[filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.\]

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

T A C

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must be female.
* The patient must be greater than or equal to 18 years of age and less than or equal to 70 years of age.
* The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination.
* The breast cancer must be HER2-negative based on current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. If the result of the in situ hybridization testing (FISH, chromagen in situ hybridization (CISH), or other) is equivocal, the patient is eligible if there is no plan to administer HER2-targeted therapy.
* All of the following staging criteria (according to the 6th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual) must be met: By pathologic evaluation, primary tumor must be pT1-3; By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b. If pN0, at least one of the following criteria must be met: ER negative and PgR negative; or Pathologic tumor size greater than 2.0 cm; or T1c (pathologic tumor size greater than 1.0 cm but less than or equal to 2.0 cm) and ER positive (PgR status may be positive or negative) and either Oncotype DX® Recurrence Score of greater than or equal to 25 or grade 3 histology.
* Patients must have undergone either a total mastectomy or breast-conserving surgery (lumpectomy).
* For patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and DCIS as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional operative procedures must be performed to obtain clear margins. If tumor is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. (Patients with margins positive for lobular carcinoma in situ \[LCIS\] are eligible without additional resection.)
* For patients who undergo mastectomy, margins must be histologically free of invasive tumor and DCIS.
* Patients must have completed one of the following procedures for evaluation of pathologic nodal status: Sentinel lymphadenectomy alone if pathologic nodal staging based on sentinel lymphadenectomy is pN0, pN1mi, or pN1b; Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph nodes if the sentinel node (SN) is positive; or Axillary lymphadenectomy without SN isolation procedure.
* The interval between the last surgery for breast cancer (treatment or staging) and randomization must be at least 28 days but no more than 84 days.
* Patients must have ER analysis performed on the primary tumor prior to randomization. If ER analysis is negative, then PgR analysis must also be performed. (Either a core biopsy or surgical resection specimen can be used for ER/PgR testing.)
* The most recent postoperative blood counts must meet the following criteria: Absolute neutrophil count (ANC) must be greater than or equal to 1200/mm3; platelet count must be greater than or equal to 100,000/mm3; and hemoglobin must be greater than or equal to 10 g/dL.
* The following criteria for evidence of adequate hepatic function must be met based on the results of the most recent postoperative tests: total bilirubin must be less than or equal to upper limits of normal (ULN)for the lab unless the patient has a bilirubin elevation less than ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab; and AST must be less than or equal to 1.5 x ULN for the lab. Alkaline phosphatase and aspartate transaminase (AST) may not both be greater than the ULN. For example, if the alkaline phosphatase is greater than the ULN but less than or equal to 2.5 x ULN, then the AST must be less than or equal to the ULN. If the AST is greater than the ULN but less than or equal to 1.5 x ULN, then the alkaline phosphatase must be less than or equal to ULN.
* Patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion in the study if liver imaging (CT, MRI, PET-CT, or PET scan) does not demonstrate metastatic disease and the requirements for adequate hepatic function are met.
* Patients with alkaline phosphatase that is greater than ULN but less than or equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan, PET-CT, or PET scan does not demonstrate metastatic disease.
* The most recent postoperative serum creatinine must be less than or equal to ULN for the lab.
* A urine sample must be tested for proteinuria by the dipstick method. Eligibility must be based on the most recent postoperative test result(s) performed within 6 weeks prior to randomization. Urine dipstick must indicate 0-1+ protein. If dipstick reading is greater than or equal to 2+, a 24-hour urine specimen must be collected and must demonstrate less than 1 gram of protein.
* Left ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or multigated acquisition (MUGA) scan must be performed within 90 days prior to randomization. The LVEF must be greater than or equal to 50% regardless of the facility's lower limits of normal (LLN).

Exclusion Criteria

* T4 tumors including inflammatory breast cancer.
* Definitive clinical or radiologic evidence of metastatic disease.
* Synchronous or metachronous contralateral invasive breast cancer. (Patients with synchronous and/or metachronous contralateral DCIS are eligible.)
* Any history of ipsilateral invasive breast cancer or ipsilateral DCIS.
* History of non-breast malignancies within 5 years prior to randomization, except for the following: carcinoma in situ of the cervix, colorectal carcinoma in situ, melanoma in situ, and basal cell and squamous cell carcinomas of the skin.
* Previous therapy with anthracyclines, taxanes, or bevacizumab for any malignancy.
* Chemotherapy administered for the currently diagnosed breast cancer prior to randomization.
* Continued therapy with any hormonal agent such as raloxifene or tamoxifen (or other SERM) or an aromatase inhibitor. (Patients are eligible if these medications are discontinued prior to randomization.)
* Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy. Patients are eligible if these medications are discontinued prior to randomization.
* Active hepatitis B or hepatitis C with abnormal liver function tests.
* Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens. This includes but is not confined to 1) Active cardiac disease: angina pectoris that requires the use of anti-anginal medication; ventricular arrhythmias except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; conduction abnormality requiring a pacemaker; valvular disease with documented compromise in cardiac function; and symptomatic pericarditis, 2) History of cardiac disease: myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function; history of documented congestive heart failure (CHF); and documented cardiomyopathy.
* Uncontrolled hypertension defined as systolic BP greater than 150 mmHg or diastolic BP greater than 90 mmHg, with or without anti-hypertensive medication. Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.
* History of hypertensive crisis or hypertensive encephalopathy.
* History of transient ischemic attack (TIA) or cerebrovascular accident (CVA).
* History of any arterial thrombotic event within 12 months prior to randomization.
* Symptomatic peripheral vascular disease.
* Intrinsic lung disease resulting in dyspnea.
* Unstable diabetes mellitus.
* Active infection or chronic infection requiring suppressive antibiotics.
* History of a major organ allograft or condition requiring chronic immunosuppression, e.g., kidney, liver, lung, heart, bone marrow transplant, or autoimmune diseases. (Patients who have received corneal transplants, cadaver skin, or bone transplants are eligible.)
* Any significant bleeding within 180 days prior to randomization, exclusive of menorrhagia in premenopausal women.
* Non-healing wound, skin ulcers, or incompletely healed bone fracture.
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the planned start of study therapy.
* Anticipation of need for major surgical procedures during study therapy and for at least 3 months following completion of bevacizumab.
* Gastroduodenal ulcer(s) documented by endoscopy to be active within 6 months before randomization.
* History of GI perforation, abdominal fistulae, or intra-abdominal abscess.
* Known bleeding diathesis or coagulopathy.
* Requirement for therapeutic doses of coumadin or equivalent.
* Sensory/motor neuropathy greater than or equal to grade 2, as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
* Conditions that would prohibit administration of corticosteroids.
* Chronic daily treatment with corticosteroids (dose of greater than or equal to 10 mg/day methylprednisolone equivalent) (excluding inhaled steroids).
* History of hypersensitivity reaction to drugs formulated with polysorbate 80.
* Pregnancy or lactation at the time of study entry.
* Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up.
* Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.
* Use of any investigational product within 4 weeks prior to randomization.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Genentech, Inc.

INDUSTRY

Sponsor Role collaborator

US Oncology Research

INDUSTRY

Sponsor Role collaborator

NSABP Foundation Inc

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Norman Wolmark, MD

Role: PRINCIPAL_INVESTIGATOR

NSABP Foundation Inc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Birmingham Hematology and Oncology

Bessemer, Alabama, United States

Site Status

Birmingham Hematology and Oncology

Birmingham, Alabama, United States

Site Status

Birmingham Hematology and Oncology - Brookwood

Birmingham, Alabama, United States

Site Status

Birmingham Hematology and Oncology - Princeton

Birmingham, Alabama, United States

Site Status

Birmingham Hematology and Oncology - Montclair

Birmingham, Alabama, United States

Site Status

Birmingham Hematology and Oncology - Pilot

Birmingham, Alabama, United States

Site Status

Clearview Cancer Institute- Huntsville

Huntsville, Alabama, United States

Site Status

Northern Arizona Hematology & Onclogy Associates

Flagstaff, Arizona, United States

Site Status

Arizona Oncolocy (CASA-Green Valley)

Green Valley, Arizona, United States

Site Status

Arizona Oncology (CASA- Oro Valley)

Oro Valley, Arizona, United States

Site Status

Hematology Oncology Associates

Phoenix, Arizona, United States

Site Status

Northern Arizona Hematology & Oncology Associates

Prescott Valley, Arizona, United States

Site Status

Arizona Oncology (CASA-Safford)

Safford, Arizona, United States

Site Status

Hematology Oncology Associates

Scottsdale, Arizona, United States

Site Status

Northern Arizona Hematology & Oncology Associates

Sedona, Arizona, United States

Site Status

Arizona Oncology Associates - Rudasill

Tucson, Arizona, United States

Site Status

Arizona Oncology Associates - Carondelet

Tucson, Arizona, United States

Site Status

Arizona Oncology (CASA-Craycroft)

Tucson, Arizona, United States

Site Status

Arizona Oncology (CASA-Office Only)

Tucson, Arizona, United States

Site Status

Arizona Oncology - CASA St. Mary's

Tucson, Arizona, United States

Site Status

Central Hematology/Oncology Medical Group, Inc.

Alhambra, California, United States

Site Status

Kaiser Permanente Deer Valley Med Center

Antioch, California, United States

Site Status

Comp Blook and Cancer Center

Bakersfield, California, United States

Site Status

Southwest Cancer Care (E. Grand)

Escondido, California, United States

Site Status

Kaiser Permanente Fremont

Fremont, California, United States

Site Status

St. Jude Heritage Healthcare

Fullerton, California, United States

Site Status

Kaiser Permanente Medical Center - Hayward

Hayward, California, United States

Site Status

Pacific Shores Medical Group

Huntington Beach, California, United States

Site Status

Southern California Permanente Medical Group

Irvine, California, United States

Site Status

Wilshire Oncology Medical Group (Business Office)

La Verne, California, United States

Site Status

Antelope Valley Cancer Center

Lancaster, California, United States

Site Status

Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center

Long Beach, California, United States

Site Status

Todd Cancer Institute at Long Beach Memorial Med Cent

Long Beach, California, United States

Site Status

Pacific Shores Medical Group

Long Beach, California, United States

Site Status

Pacific Shores Medical Group

Los Alamitos, California, United States

Site Status

TORI- N Valley Hematology Oncology Med Group

Mission Hills, California, United States

Site Status

TORI - Oncology Care Medical Assoc.

Montebello, California, United States

Site Status

Southwest Cancer Care (Medical Center)

Murrieta, California, United States

Site Status

NValley Hematology/Oncology Medical Group

Northridge, California, United States

Site Status

Kaiser Permanente-Oakland

Oakland, California, United States

Site Status

St. Joseph Hospital

Orange, California, United States

Site Status

Ventura County Hematology-Oncology Specialists

Oxnard, California, United States

Site Status

Stanford University Medical Center

Palo Alto, California, United States

Site Status

Kaiser Permanente Medical Center - Redwood City

Redwood City, California, United States

Site Status

Kaiser Permanente Medical Center - Richmond

Richmond, California, United States

Site Status

Sutter Roseville Medical Center

Roseville, California, United States

Site Status

Kaiser Permanente Roseville

Roseville, California, United States

Site Status

Sutter Medical Center

Sacramento, California, United States

Site Status

Kaiser Permanente, South Sacramento

Sacramento, California, United States

Site Status

Kaiser Permanente Medical Center - Sacramento

Sacramento, California, United States

Site Status

Kaiser Permanente-San Diego

San Diego, California, United States

Site Status

Kaiser Permanente Medical Center - San Francisco Geary Campus

San Francisco, California, United States

Site Status

TORI - Oncology Care Med Assoc

San Gabriel, California, United States

Site Status

Kaiser Permanente Santa Teresa

San Jose, California, United States

Site Status

Kaiser Permanente San Rafael

San Rafael, California, United States

Site Status

Santa Barbara Hematology Oncology Medical Group

Santa Barbara, California, United States

Site Status

Santa Barbara II (Samsum Clinic) - TORI

Santa Barbara, California, United States

Site Status

Kaiser Permanente Medical Center - Santa Clara Kiely Campus

Santa Clara, California, United States

Site Status

Central Coast Medical Oncology Corporation

Santa Maria, California, United States

Site Status

Kaiser Permanente Medical Center - Santa Rosa

Santa Rosa, California, United States

Site Status

Santa Barbara Hematology/Oncology Medical Group, Inc

Solvang, California, United States

Site Status

Kaiser Permanente-South San Francisco

South San Francisco, California, United States

Site Status

Kaiser Permanente Medical Facility - Stockton

Stockton, California, United States

Site Status

Olive View/UCLA Medical Center

Sylmar, California, United States

Site Status

Kaiser Permanente Medical Center Vacaville

Vacaville, California, United States

Site Status

Kaiser Permanente Medical Center - Vallejo

Vallejo, California, United States

Site Status

Kaiser Permanente Medical Center - Walnut Creek

Walnut Creek, California, United States

Site Status

Trivalley Oncology Hematology

Westlake Village, California, United States

Site Status

Westlake Infusion Center

Westlake Village, California, United States

Site Status

TORI - Oncology Care Med Assoc

Whittier, California, United States

Site Status

Medical Center of Aurora

Aurora, Colorado, United States

Site Status

Rocky Mountain Cancer Center

Aurora, Colorado, United States

Site Status

Rocky Mountain Cancer Centers - Boulder

Boulder, Colorado, United States

Site Status

Penrose/St. Francis Healthcare System

Colorado Springs, Colorado, United States

Site Status

Rocky Mountain Cancer Center at the Pivillion- Fontanero

Colorado Springs, Colorado, United States

Site Status

Rocky Mountain Cancer Center - CO Springs

Colorado Springs, Colorado, United States

Site Status

Kaiser Permanente-Franklin

Denver, Colorado, United States

Site Status

CCOP - Colorado Cancer Research Program, Inc.

Denver, Colorado, United States

Site Status

Porter Adventist Hospital

Denver, Colorado, United States

Site Status

Exempla St. Joseph Hospital

Denver, Colorado, United States

Site Status

Rocky Mountain Cancer Center - Midtown

Denver, Colorado, United States

Site Status

Rocky Mountain Cancer Center - 9th Avenue

Denver, Colorado, United States

Site Status

Rocky Mountain Cancer Center - Rose

Denver, Colorado, United States

Site Status

University of Colorado

Denver, Colorado, United States

Site Status

Shaw Regional Cancer Center

Edwards, Colorado, United States

Site Status

Swedish Medical Center

Englewood, Colorado, United States

Site Status

Front Range Cancer Specialists

Fort Collins, Colorado, United States

Site Status

Poudre Valley Hospital

Fort Collins, Colorado, United States

Site Status

St. Mary's Hospital and Medical Center

Grand Junction, Colorado, United States

Site Status

St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center

Grand Junction, Colorado, United States

Site Status

North Colorado Medical Center

Greeley, Colorado, United States

Site Status

Kaiser Permanente Rock Creek

Lafayette, Colorado, United States

Site Status

Rocky Mountain Cancer Center

Lakewood, Colorado, United States

Site Status

Rocky Mountain Cancer Center - Dry Creek

Littleton, Colorado, United States

Site Status

Rocky Mountain Cancer Center- Sky Ridge

Lone Tree, Colorado, United States

Site Status

Rocky Mountain Cancer Center - Longmont

Longmont, Colorado, United States

Site Status

McKee Medical Center

Loveland, Colorado, United States

Site Status

Rocky Mountain Cancer Center

Parker, Colorado, United States

Site Status

Rocky Mountain Cancer Centers

Thornton, Colorado, United States

Site Status

Exempla Lutheran Medical Center

Wheat Ridge, Colorado, United States

Site Status

University of Connecticut

Farmington, Connecticut, United States

Site Status

Hartford Hospital

Hartford, Connecticut, United States

Site Status

Washington Regional Cancer Center

Washington D.C., District of Columbia, United States

Site Status

Sibley Memorial Hospital

Washington D.C., District of Columbia, United States

Site Status

SCRI - Florida Cancer Specialists- Bonita Springs

Bonita Springs, Florida, United States

Site Status

SCRI - Florida Cancer Specialists - Bradenton

Bradenton, Florida, United States

Site Status

Florida Cancer Specialists

Brandon, Florida, United States

Site Status

SCRI Florida Cancer Specialists - Cape Coral (1708)

Cape Coral, Florida, United States

Site Status

SCRI Florida Cancer Specialists - Cape Coral (811)

Cape Coral, Florida, United States

Site Status

Morton Plant Mease Health Care

Clearwater, Florida, United States

Site Status

SCRI Florida Cancer Specialists - Englewood

Englewood, Florida, United States

Site Status

Holy Cross Hospital

Fort Lauderdale, Florida, United States

Site Status

SCRI Florida Cancer Specialists - Fort Myers (Hampshire)

Fort Myers, Florida, United States

Site Status

SCRI Florida Cancer Specialists - Ft. Myers (Broadway)

Fort Myers, Florida, United States

Site Status

SCRI Florida Cancer Specialists- Fort Myers (Veronica)

Fort Myers, Florida, United States

Site Status

University of Florida Shands Cancer Center

Gainesville, Florida, United States

Site Status

Florida Cancer Institute - New Hope

Hudson, Florida, United States

Site Status

TORI-ICON - Shircl

Jacksonville, Florida, United States

Site Status

Baptist Cancer Institute - Jacksonville

Jacksonville, Florida, United States

Site Status

Integrated Community Oncology Network (ICON)

Jacksonville, Florida, United States

Site Status

TORI-ICON St.Aug

Jacksonville, Florida, United States

Site Status

CCOP, Jupiter Medical Cener

Jupiter, Florida, United States

Site Status

Ocala Oncology Center - Lady Lake

Lady Lake, Florida, United States

Site Status

Melbourne International Medicine Associates

Melbourne, Florida, United States

Site Status

Advanced Medical Specialties - AMS

Miami, Florida, United States

Site Status

Advanced Medical Specialists- Sunset

Miami, Florida, United States

Site Status

Advanced Medical Specialties - N Kendall (STE 300E)

Miami, Florida, United States

Site Status

Advanced Medical Specialties - N. Kendall (STE 905E)

Miami, Florida, United States

Site Status

CCOP - Mount Sinai Medical Center

Miami Beach, Florida, United States

Site Status

SCRI Florida Cancer Specialists - Naples (Goodlette)

Naples, Florida, United States

Site Status

SCRI Florida Cancer Specialists - Naples (Pine)

Naples, Florida, United States

Site Status

Florida Cancer Institute - New Hope

New Port Richey, Florida, United States

Site Status

Ocala Oncology Center

Ocala, Florida, United States

Site Status

Cancer Centers of Florida, P.A.

Ocoee, Florida, United States

Site Status

Tori-Icon

Orange Park, Florida, United States

Site Status

Florida Hospital

Orlando, Florida, United States

Site Status

Cancer Centers of Florida, P.A.

Orlando, Florida, United States

Site Status

MD Anderson Cancer Center

Orlando, Florida, United States

Site Status

SCRI - Florida Cancer Specialists - Port Charlotte

Port Charlotte, Florida, United States

Site Status

Tori-Icon

Saint Augustine, Florida, United States

Site Status

SCRI Florida Cancer Specialists - Sarasota (Cattleman)

Sarasota, Florida, United States

Site Status

SCRI- Florida Cancer Specialists - Sarasota

Sarasota, Florida, United States

Site Status

SCRI - Florida Cancer Specialists - Armenia

Tampa, Florida, United States

Site Status

SCRI - Florida Cancer Specialists - Tampa

Tampa, Florida, United States

Site Status

SCRI Florida Cancer Specialists - Venice (Tamiami)

Venice, Florida, United States

Site Status

SCRI Florida Cancer Specilaists - Venice

Venice, Florida, United States

Site Status

Cancer Centers of Florida, P.A.

Winter Park, Florida, United States

Site Status

Phoebe Putney Memorial Hospital

Albany, Georgia, United States

Site Status

Northwest Georgia Oncology Centers

Austell, Georgia, United States

Site Status

Northwest Georgia Oncology Centers

Carrollton, Georgia, United States

Site Status

Dublin Hematology/Oncology

Dublin, Georgia, United States

Site Status

Suburban Hematology-Oncology Associates

Lawrenceville, Georgia, United States

Site Status

Northwest Georgia Oncology Centers

Marietta, Georgia, United States

Site Status

SCRI Chattanooga Oncol & Hematol Assoc, PC - Ringgold

Ringgold, Georgia, United States

Site Status

Memorial Health University Medical Center

Savannah, Georgia, United States

Site Status

University of Hawaii

Honolulu, Hawaii, United States

Site Status

Kaiser Permanente Hawaii - Moanalua Med Center

Honolulu, Hawaii, United States

Site Status

Cancer Care & Hematology Specialists of Chicagoland

Arlington, Illinois, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Decatur Memorial Hospital Cancer Care Institute

Decatur, Illinois, United States

Site Status

CCOP NorthShore University HealthSystem

Evanston, Illinois, United States

Site Status

Ingalls Memorial Hospital

Harvey, Illinois, United States

Site Status

Hinsdale Hematology Oncology Associates

Hinsdale, Illinois, United States

Site Status

Edward Hospital

Naperville, Illinois, United States

Site Status

Cancer Care & Hematology Specialists of Chicagoland

Niles, Illinois, United States

Site Status

Advocate Lutheran General Cancer Care Center

Park Ridge, Illinois, United States

Site Status

Carle Cancer Center, CCOP

Urbana, Illinois, United States

Site Status

Carle Foundation Hospital

Urbana, Illinois, United States

Site Status

Cancer Care and Hematology Specialists of Chicagoland

Winfield, Illinois, United States

Site Status

Central Indiana Cancer Centers

Carmel, Indiana, United States

Site Status

Central Indiana Cancer Centers

Fishers, Indiana, United States

Site Status

Central Indiana Cancer Centers

Greenfield, Indiana, United States

Site Status

Central Indiana Cancer Centers

Indianapolis, Indiana, United States

Site Status

Central Indiana Cancer Centers (E. County)

Indianapolis, Indiana, United States

Site Status

St. Vincent Hospital and Health Care Center

Indianapolis, Indiana, United States

Site Status

Clarian Arnett Cancer Care

Lafayette, Indiana, United States

Site Status

Community Hospital

Munster, Indiana, United States

Site Status

Genesis Medical Center

Davenport, Iowa, United States

Site Status

Finley Hospital

Dubuque, Iowa, United States

Site Status

University of Iowa

Iowa City, Iowa, United States

Site Status

Mercy Medical Center - Sioux City

Sioux City, Iowa, United States

Site Status

Siouxland Hematology-Oncology Associates

Sioux City, Iowa, United States

Site Status

St. Luke's Regional Medical Center

Sioux City, Iowa, United States

Site Status

Covenant Cancer Treatment Center

Waterloo, Iowa, United States

Site Status

Kansas Cty Cancer Center - West

Kansas City, Kansas, United States

Site Status

Menorah Medical Center

Overland Park, Kansas, United States

Site Status

Kansas City Cancer Center (CBO)

Overland Park, Kansas, United States

Site Status

Kansas CityCancer Centers - Southwest

Overland Park, Kansas, United States

Site Status

Kansas City Cancer Center, Shawnee Mission

Shawnee Mission, Kansas, United States

Site Status

SCRI Oncology Hematology Care, Inc. Crestview Hills (CVH)

Crestview Hills, Kentucky, United States

Site Status

University of Kentucky Medical Center

Lexington, Kentucky, United States

Site Status

NortonHealtcare Inc.

Louisville, Kentucky, United States

Site Status

Consultants in Blood Disorders and Cancer

Louisville, Kentucky, United States

Site Status

Christus St. Frances Cabrini Hospital

Alexandria, Louisiana, United States

Site Status

Baton Rouge General Medical Center

Baton Rouge, Louisiana, United States

Site Status

Tulane University Medical Center

New Orleans, Louisiana, United States

Site Status

Eastern Maine Medical Center

Bangor, Maine, United States

Site Status

Mercy Medical Center

Baltimore, Maryland, United States

Site Status

St. Joseph's Medical Center

Baltimore, Maryland, United States

Site Status

Greater Baltimore Medical Center

Baltimore, Maryland, United States

Site Status

Franklin Square Hospital Center

Baltimore, Maryland, United States

Site Status

SCRI - Center for Cancer and Blood Disorders

Bethesda, Maryland, United States

Site Status

Suburban Hospital

Bethesda, Maryland, United States

Site Status

Chevy Chase Healthcare Management, LLC

Chevy Chase, Maryland, United States

Site Status

Maryland Oncology Hematology PA

Columbia, Maryland, United States

Site Status

Frederick Memorial Hospital

Frederick, Maryland, United States

Site Status

Alliance Hematology Oncology PA

Owings Mills, Maryland, United States

Site Status

Penisula Regional Medical Center

Salisbury, Maryland, United States

Site Status

Holy Cross Hospital

Silver Spring, Maryland, United States

Site Status

Alliance Hematology Oncology PA

Westminster, Maryland, United States

Site Status

Saint Anne's Hospital

Fall River, Massachusetts, United States

Site Status

Berkshire Hematology Oncology, P.C.

Pittsfield, Massachusetts, United States

Site Status

CCOP, St. Joseph Mercy Hospital

Ann Arbor, Michigan, United States

Site Status

Bay Regional Medical Center

Bay City, Michigan, United States

Site Status

CCOP - Oakwood Hospital and Medical Center

Dearborn, Michigan, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

CCOP - St. John Hospital and Medical Center

Detroit, Michigan, United States

Site Status

Michigan State University

East Lansing, Michigan, United States

Site Status

CCOP - Genesys Regional Hospital

Flint, Michigan, United States

Site Status

CCOP - Hurley Medical Center

Flint, Michigan, United States

Site Status

McLaren Regional Medical Center

Flint, Michigan, United States

Site Status

CCOP - Allegiance Health

Jackson, Michigan, United States

Site Status

Borgess Medical Center

Kalamazoo, Michigan, United States

Site Status

Bronson Methodist Hospital

Kalamazoo, Michigan, United States

Site Status

West Michigan Cancer Center

Kalamazoo, Michigan, United States

Site Status

Ingham Regional Medical Center - Lansing

Lansing, Michigan, United States

Site Status

CCOP, Sparrow Health System

Lansing, Michigan, United States

Site Status

Lapeer Regional Hospital

Lapeer, Michigan, United States

Site Status

CCOP - St. Mary Mercy Hospital - Livonia

Livonia, Michigan, United States

Site Status

Marquette General Hospital

Marquette, Michigan, United States

Site Status

Mount Clemens Regional Medical Center

Mount Clemens, Michigan, United States

Site Status

Memorial Healthcare

Owosso, Michigan, United States

Site Status

CCOP - St. Joseph Mercy Hospital - Oakland

Pontiac, Michigan, United States

Site Status

CCOP - St. Joseph Mercy Port Huron

Port Huron, Michigan, United States

Site Status

CCOP, William Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

CCOP, St. Mary's Medical Center

Saginaw, Michigan, United States

Site Status

Providence Hospital - Southfield

Southfield, Michigan, United States

Site Status

CCOP, St. John Macomb Hospital

Warren, Michigan, United States

Site Status

Minnesota Oncology Hematology-Burnsville

Burnsville, Minnesota, United States

Site Status

Mercy and Unity Cancer Center at Mercy Hospital

Coon Rapids, Minnesota, United States

Site Status

St. Luke's Hospital

Duluth, Minnesota, United States

Site Status

Fairview Southdale Hospital

Edina, Minnesota, United States

Site Status

Minnesota Oncology Hematology-Edina

Edina, Minnesota, United States

Site Status

Unity Hospital

Fridley, Minnesota, United States

Site Status

Minnesota Oncology Hematology PA - Maplewood

Maplewood, Minnesota, United States

Site Status

St. John's Hospital Northeast/HealthEast, Inc.

Maplewood, Minnesota, United States

Site Status

Minnesota Oncology Hematology-Minneapolis

Minneapolis, Minnesota, United States

Site Status

Abbott-Northwestern Hospital

Minneapolis, Minnesota, United States

Site Status

Hennepin County Medical Center - Minneapolis

Minneapolis, Minnesota, United States

Site Status

North Memorial Health Care

Robbinsdale, Minnesota, United States

Site Status

CCOP - Metro-Minnesota

Saint Louis Park, Minnesota, United States

Site Status

Park Nicollet Health Services

Saint Louis Park, Minnesota, United States

Site Status

Regions Hospital Cancer Care Center

Saint Paul, Minnesota, United States

Site Status

Minnesota Hematology Oncology-St. Paul

Saint Paul, Minnesota, United States

Site Status

Minnesota Oncology Hematology

Woodbury, Minnesota, United States

Site Status

Missouri Cancer Associates

Columbia, Missouri, United States

Site Status

University of Missouri-Ellis Fischel

Columbia, Missouri, United States

Site Status

Kansas City Cancer Center - Central

Kansas City, Missouri, United States

Site Status

Saint Luke's Hospital

Kansas City, Missouri, United States

Site Status

CCOP - Kansas City

Kansas City, Missouri, United States

Site Status

Kansas City Cancer Center - South

Kansas City, Missouri, United States

Site Status

Research Medical Center

Kansas City, Missouri, United States

Site Status

Research Medical Center

Kansas City, Missouri, United States

Site Status

Kansas City Cancer Center - North

Kansas City, Missouri, United States

Site Status

Kansas City Cancer Centers - East

Lee's Summit, Missouri, United States

Site Status

St. Louis University Health Sciences Center

St Louis, Missouri, United States

Site Status

Nebraska Cancer Research Center

Lincoln, Nebraska, United States

Site Status

St. Elizabeth Community Health Center

Lincoln, Nebraska, United States

Site Status

Alegent Health Immanuel Medical Center

Omaha, Nebraska, United States

Site Status

Alegent Health Bergan Mercy Medical Center

Omaha, Nebraska, United States

Site Status

CCOP, Missouri Valley Cance Consortium

Omaha, Nebraska, United States

Site Status

Creighton University Cancer Center

Omaha, Nebraska, United States

Site Status

Alegent Health Midlands Hospital

Papillion, Nebraska, United States

Site Status

Comprehensive Cancer Centers of Nevada (Siena)

Henderson, Nevada, United States

Site Status

US Oncology West Region Office (Horizon Ridge)

Henderson, Nevada, United States

Site Status

Comprehensive Cancer Centers of Nevada (Wigwam)

Henderson, Nevada, United States

Site Status

Comprehensive Cancer Centers of Nevada (Peak Dr.)

Las Vegas, Nevada, United States

Site Status

Comprehensive Cancer Centers of Nevada (Southern Hills)

Las Vegas, Nevada, United States

Site Status

Comprehensive Cancer Centers of Nevada (Twain)

Las Vegas, Nevada, United States

Site Status

Renown Regional Medical Center

Reno, Nevada, United States

Site Status

Cancer Institute of New Jersey at Hamilton

Hamilton, New Jersey, United States

Site Status

Hematology-Oncology Associates of NNJ, PA

Morristown, New Jersey, United States

Site Status

Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Site Status

Newark Beth Israel Medical Center

Newark, New Jersey, United States

Site Status

Saint Clare's Center at Parsippany Commons

Parsippany, New Jersey, United States

Site Status

Somerset Medical Center

Somerville, New Jersey, United States

Site Status

Sparta Cancer Center

Sparta, New Jersey, United States

Site Status

Texas Oncology PA Las Cruces

Las Cruces, New Mexico, United States

Site Status

New Mexico Cancer Care Associates

Santa Fe, New Mexico, United States

Site Status

New York Oncology Hematology PC-Albany

Albany, New York, United States

Site Status

New York Oncology Hematology, PC at Albany Medical Center

Albany, New York, United States

Site Status

Amsterdam Community Cancer Program

Amsterdam, New York, United States

Site Status

Interlakes Oncology Hematology PC

Brockport, New York, United States

Site Status

Interlakes Oncology & Hematology, P.C.

Canandaigua, New York, United States

Site Status

Interlakes Oncology Hematology PC

Geneva, New York, United States

Site Status

Cancer Center at Glens Falls Hospital

Glens Falls, New York, United States

Site Status

New York Oncology Hematology, P.C. at Cavell Cancer Treatment Program

Hudson, New York, United States

Site Status

New York Oncology Hematology, PC

Latham, New York, United States

Site Status

CCOP - North Shore University Hospital

Manhasset, New York, United States

Site Status

CCOP, Long Island Jewish Medical Center

New Hyde Park, New York, United States

Site Status

New York University School of Medicine

New York, New York, United States

Site Status

New York Oncology Hematology PC

Rexford, New York, United States

Site Status

Interlakes Oncology Hematology PC - White Spruce

Rochester, New York, United States

Site Status

Interlakes Oncology Hematology PC- Long Pond

Rochester, New York, United States

Site Status

University Hospital and Medical Center - SUNY Stony Brook

Stony Brook, New York, United States

Site Status

Troy Cancer Treatment Program

Troy, New York, United States

Site Status

Alamance Regional Medical Center

Burlington, North Carolina, United States

Site Status

Cancer Centers of North Carolina

Cary, North Carolina, United States

Site Status

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Site Status

CCOP Carolinas HealthCare System

Charlotte, North Carolina, United States

Site Status

Presbyterian Hospital

Charlotte, North Carolina, United States

Site Status

Regional Cancer Care, PA

Durham, North Carolina, United States

Site Status

Virginia Oncology Associates

Elizabeth City, North Carolina, United States

Site Status

Cape Fear Valley Medical Center Cancer Center

Fayetteville, North Carolina, United States

Site Status

Wayne Memorial Hospital, Incorporated

Goldsboro, North Carolina, United States

Site Status

CCOP, Moses Cone Health System-Regional CA Cntr

Greensboro, North Carolina, United States

Site Status

East Carolina University

Greenville, North Carolina, United States

Site Status

Margaret R. Pardee Memorial Hospital

Hendersonville, North Carolina, United States

Site Status

High Point Regional Hospital

High Point, North Carolina, United States

Site Status

Cancer Centers of North Carolina

Raleigh, North Carolina, United States

Site Status

Cancer Centers of North Carolina- North Raleigh

Raleigh, North Carolina, United States

Site Status

CCOP Forsyth Memorial Hospital

Winston-Salem, North Carolina, United States

Site Status

Innovis Health

Fargo, North Dakota, United States

Site Status

Akron City Hospital

Akron, Ohio, United States

Site Status

Aultman Hospital

Canton, Ohio, United States

Site Status

SCRI Oncology Hematology Care, Inc. - Cincinnati (TFT)

Cincinnati, Ohio, United States

Site Status

SCRI Oncology Hematology Care, Inc - Cincinnati (AND)

Cincinnati, Ohio, United States

Site Status

SCRI Oncology Hematology Care, Inc. - Cincinnati (KWD)

Cincinnati, Ohio, United States

Site Status

SCRI Oncology Hematlogy Care, Inc. - Cincinnati (RPR)

Cincinnati, Ohio, United States

Site Status

SCRI Oncology Hematology Care, Inc - Cincinnati (BAM)

Cincinnati, Ohio, United States

Site Status

SCRI Oncology Hematology Care, Inc. Cincinnati (WST)

Cincinnati, Ohio, United States

Site Status

Good Samaritan Hospital

Dayton, Ohio, United States

Site Status

CCOP - Dayton

Dayton, Ohio, United States

Site Status

HemOnc Care, Inc.

Fairfield, Ohio, United States

Site Status

Atrium Medical Center - Middletown Regional Hosp

Franklin, Ohio, United States

Site Status

Wayne Hospital

Greenville, Ohio, United States

Site Status

SCRI Oncology Hematology Care, Inc. - Hamilton (HAM)

Hamilton, Ohio, United States

Site Status

Greater Dayton Cancer Center

Kettering, Ohio, United States

Site Status

Kettering Medical Center

Kettering, Ohio, United States

Site Status

Upper Valley Medical Center

Troy, Ohio, United States

Site Status

Clinton Memorial Hospital

Wilmington, Ohio, United States

Site Status

SCRI Oncology Hematology Care, Inc. - Wilmington (WLM)

Wilmington, Ohio, United States

Site Status

St. Charles Medical Center - Bend

Bend, Oregon, United States

Site Status

Willamette Valley Cancer Institute and Research Center

Eugene, Oregon, United States

Site Status

Northwest Cancer Specialists-Portland

Portland, Oregon, United States

Site Status

Providence Medical Center

Portland, Oregon, United States

Site Status

Northwest Cancer Specialists- St. Vincent

Portland, Oregon, United States

Site Status

Providence St. Vincent Medical Center

Portland, Oregon, United States

Site Status

Northwest Cancer Specialists- Rose Qtr

Portland, Oregon, United States

Site Status

Williamette Valley Cancer Institute and Research Center

Springfield, Oregon, United States

Site Status

Celilo Center for Cancer Care

The Dalles, Oregon, United States

Site Status

Northwest Cancer Specialists-Tualatin

Tualatin, Oregon, United States

Site Status

Geisinger Clinic

Danville, Pennsylvania, United States

Site Status

Oncology Hematology Associates of Northern PA

DuBois, Pennsylvania, United States

Site Status

Pocono Medical Center

East Stroudsburg, Pennsylvania, United States

Site Status

Ephrata Community Hopital

Ephrata, Pennsylvania, United States

Site Status

Geisinger Hazleton Cancer Center

Hazleton, Pennsylvania, United States

Site Status

Medical Oncology Associates

Kingston, Pennsylvania, United States

Site Status

Riddle Memorial Hospital

Media, Pennsylvania, United States

Site Status

Rittenhouse Hematology/Oncology

Philadelphia, Pennsylvania, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Albert Einstein Healthcare Network

Philadelphia, Pennsylvania, United States

Site Status

Allegheny General Hospital/Allegheny-Singer Research Institute

Pittsburgh, Pennsylvania, United States

Site Status

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

Hematology and Oncology Associates of NEPA

Scranton, Pennsylvania, United States

Site Status

Scranton Hematology Oncology

Scranton, Pennsylvania, United States

Site Status

Geisinger Medical Group - Scenery Park

State College, Pennsylvania, United States

Site Status

Associates in Hematology-Oncology, PC at Crozer Regional Cancer Center

Upland, Pennsylvania, United States

Site Status

Reading Hospital and Medical Center

West Reading, Pennsylvania, United States

Site Status

Geisinger Wyoming Valley Medical Center

Wilkes-Barre, Pennsylvania, United States

Site Status

AnMed Health Cancer Center

Anderson, South Carolina, United States

Site Status

Roper Hosp & Med Asso (Care Alliance Health)

Charleston, South Carolina, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

SCRI - South Carolina Oncology Associates - Stoneridge

Columbia, South Carolina, United States

Site Status

Cancer Centers of the Carolinas Easley, SC

Easley, South Carolina, United States

Site Status

Georgetown Hospital System

Georgetown, South Carolina, United States

Site Status

Cancer Centers of the Carolinas (Butternut)

Greenville, South Carolina, United States

Site Status

Cancer Centers of the Carolinas-W. Faris Road

Greenville, South Carolina, United States

Site Status

Cancer Centers of the Carolinas (International)

Greenville, South Carolina, United States

Site Status

Cancer Centers of the Carolinas - Seneca

Seneca, South Carolina, United States

Site Status

Spartanburg Regional Healthcare System

Spartanburg, South Carolina, United States

Site Status

Cancer Centers of the Carolinas - Spartanburg

Spartanburg, South Carolina, United States

Site Status

Avera McKenna Hospital

Sioux Falls, South Dakota, United States

Site Status

Avera Cancer Institute

Sioux Falls, South Dakota, United States

Site Status

CCOP, Sanford Cancer Center - Oncology Clinic

Sioux Falls, South Dakota, United States

Site Status

SCRI Chattanooga Oncol & Hematol Assoc, PC - Chattanooga

Chattanooga, Tennessee, United States

Site Status

SCRI Tennessee Oncology - PLLC Franklin

Franklin, Tennessee, United States

Site Status

SCRI Tennessee Oncology- Gallatin

Gallatin, Tennessee, United States

Site Status

SCRI Tennessee Oncology, PLLC Hermitage

Hermitage, Tennessee, United States

Site Status

SCRI Chattanooga Oncol & Hematol Assoc, PC Hixson

Hixson, Tennessee, United States

Site Status

CCOP Holston Valley Medical Center

Kingsport, Tennessee, United States

Site Status

SCRI Tennessee Oncology Lebanon

Lebanon, Tennessee, United States

Site Status

SCRI Tennessee Oncology Murfreesboro

Murfreesboro, Tennessee, United States

Site Status

SCRI - Tennessee Oncology PLLC

Nashville, Tennessee, United States

Site Status

SCRI Tennessee Oncology, PLLC (Harding)

Nashville, Tennessee, United States

Site Status

SCRI Tennessee Onclogy, PLLC (Dickerson)

Nashville, Tennessee, United States

Site Status

SCRI - Tennessee Oncology PLLC

Nashville, Tennessee, United States

Site Status

SCRI Tennessee Oncology, PLLC (Wallace)

Nashville, Tennessee, United States

Site Status

Tennessee Oncology

Shelbyville, Tennessee, United States

Site Status

SCRI Tennessee Oncology, PLLC Smyrna

Smyrna, Tennessee, United States

Site Status

Texas Cancer Center - Abilene South

Abilene, Texas, United States

Site Status

Texas Oncology PA - Amarillo

Amarillo, Texas, United States

Site Status

Texas Oncology PA - Arlington North

Arlington, Texas, United States

Site Status

Texas Onclogy - Arlington South

Arlington, Texas, United States

Site Status

Texas Oncology Central Austin

Austin, Texas, United States

Site Status

Texas Oncology Cancer Center - Balcones

Austin, Texas, United States

Site Status

South Austin Cancer Center

Austin, Texas, United States

Site Status

Southwest Regional Cancer Center- North

Austin, Texas, United States

Site Status

Texas Oncology North Austin- Renfert

Austin, Texas, United States

Site Status

Mamie McFaddin Ward Cancer Center

Beaumont, Texas, United States

Site Status

Edwards Cancer Center - Bedford

Bedford, Texas, United States

Site Status

Texas Oncology PA - Harris HEB

Bedford, Texas, United States

Site Status

Texas Oncology, PA - Cedar Park

Cedar Park, Texas, United States

Site Status

Texas Cancer Center at Medical City

Dallas, Texas, United States

Site Status

Texas Oncology PA- Presbyterian

Dallas, Texas, United States

Site Status

Methodist Charlton Cancer Center

Dallas, Texas, United States

Site Status

Texas Oncology- Sammons CC

Dallas, Texas, United States

Site Status

Texas Cancer Center

Denton, Texas, United States

Site Status

El Paso Cancer Treatment Center - West

El Paso, Texas, United States

Site Status

El Paso Cancer Treatment Center - East

El Paso, Texas, United States

Site Status

Texas Oncology - 8th Avenue

Fort Worth, Texas, United States

Site Status

Texas Oncology at Klabzuba

Fort Worth, Texas, United States

Site Status

Texas Oncology PA - 12th Avenue

Fort Worth, Texas, United States

Site Status

Southwest Fort Worth Cancer Center

Fort Worth, Texas, United States

Site Status

San Antonio Tumor and Blood Clinic

Fredericksburg, Texas, United States

Site Status

Texas Oncology PA

Garland, Texas, United States

Site Status

Texas Oncology

Grapevine, Texas, United States

Site Status

Texas Oncology PA - Frostwood

Houston, Texas, United States

Site Status

MD Anderson Cancer Center

Houston, Texas, United States

Site Status

San Antonio Tumor and Blood Clinic

Kerrville, Texas, United States

Site Status

Lake Vista Cancer Center

Lewisville, Texas, United States

Site Status

Longview Cancer Center

Longview, Texas, United States

Site Status

Joe Arrington Cancer Research & Treatment Center

Lubbock, Texas, United States

Site Status

South Texas Cancer Center - McAllen

McAllen, Texas, United States

Site Status

Texas Cancer Center of Mesquite

Mesquite, Texas, United States

Site Status

Allison Cancer Center

Midland, Texas, United States

Site Status

HOAST - New Braunfels

New Braunfels, Texas, United States

Site Status

Texas Oncology - Odessa

Odessa, Texas, United States

Site Status

Paris Regional Cancer Center

Paris, Texas, United States

Site Status

North Texas Regional Cancer Center

Plano, Texas, United States

Site Status

Texas Oncology Plano West Cancer Center

Plano, Texas, United States

Site Status

Texas Oncology Seton Williamson

Round Rock, Texas, United States

Site Status

Texas Oncology - Round Rock Cancer Center

Round Rock, Texas, United States

Site Status

Cancer Care Centers of South Texas- Brooklyn

San Antonio, Texas, United States

Site Status

Cancer Care Centers of South Texas - Loop 410

San Antonio, Texas, United States

Site Status

HOAST - Medical Drive

San Antonio, Texas, United States

Site Status

San Antonio Tumor and Blood Clinic - M.Oak

San Antonio, Texas, United States

Site Status

University of Texas Health Science Center

San Antonio, Texas, United States

Site Status

Texas Oncology - San Marcos

San Marcos, Texas, United States

Site Status

Texas Cancer Center

Sherman, Texas, United States

Site Status

Texas Oncology Cancer Center - Sugar Land

Sugar Land, Texas, United States

Site Status

US Oncology

The Woodlands, Texas, United States

Site Status

Tyler Cancer Center

Tyler, Texas, United States

Site Status

Texas Oncology Cancer Care and Research Center

Waco, Texas, United States

Site Status

Texas Oncology - Clear Lake

Webster, Texas, United States

Site Status

South Texas Cancer Clinic

Weslaco, Texas, United States

Site Status

Texoma Cancer Center

Wichita Falls, Texas, United States

Site Status

Sandra L. Maxwell Cancer Center

Cedar City, Utah, United States

Site Status

McKay-Dee Hospital Center

Ogden, Utah, United States

Site Status

Utah Valley Regional Medical Center - Provo

Provo, Utah, United States

Site Status

Huntsman Cancer Inst. at the University of Utah- Salt Lake City

Salt Lake City, Utah, United States

Site Status

LDS Hospital

Salt Lake City, Utah, United States

Site Status

Dixie Regional Medical Center - East Campus

St. George, Utah, United States

Site Status

Southwestern Regional Cancer Center (SWORD)

Bennington, Vermont, United States

Site Status

Arlington Fairfax Hematology Oncology

Arlington, Virginia, United States

Site Status

Virginia Oncology Associates - Medical Pkwy

Chesapeake, Virginia, United States

Site Status

Oncology and Hematology Associates of SW VA, Inc

Christiansburg, Virginia, United States

Site Status

Fairfax Northern VA Hematology-Oncology PC

Fairfax, Virginia, United States

Site Status

Fair Oaks Office

Fairfax, Virginia, United States

Site Status

Fairfax-Northern Virginia Hematology-Oncology PC

Gainesville, Virginia, United States

Site Status

Virginia Oncology Associates

Hampton, Virginia, United States

Site Status

Fairfax-Northern Virginia Hematology-Oncology PC

Leesburg, Virginia, United States

Site Status

SCRI Virginia Cancer Institute (Flank)

Mechanicsville, Virginia, United States

Site Status

SCRI Virginia Cancer Institute

Midlothian, Virginia, United States

Site Status

Virginia Oncology Associates

Newport News, Virginia, United States

Site Status

Virginia Oncology Associates - Lake Wright

Norfolk, Virginia, United States

Site Status

SCRI Virginia Cancer Institute (6605)

Richmond, Virginia, United States

Site Status

SCRI Virginia Cancer Institute (1401)

Richmond, Virginia, United States

Site Status

MBCCOP, Virginia Commonwealth University

Richmond, Virginia, United States

Site Status

Oncology and Hematology Associates of SW VA, Inc

Roanoke, Virginia, United States

Site Status

Oncology and Hematology Associates of SW VA, Inc

Salem, Virginia, United States

Site Status

Virginia Oncology Associates

Virginia Beach, Virginia, United States

Site Status

Virginia Oncology Associates

Williamsburg, Virginia, United States

Site Status

Fairfax Northern Virginia Hematology-Oncology - Winchester

Winchester, Virginia, United States

Site Status

Fairfax-Northern Virginia Hematology-Oncology PC

Woodbridge, Virginia, United States

Site Status

Oncology and Hematology Associates of SW VA, Inc

Wytheville, Virginia, United States

Site Status

Highline Medical Oncology

Burien, Washington, United States

Site Status

Puget Sound Cancer Center- Edmonds

Edmonds, Washington, United States

Site Status

Columbia Basin Hematology and Oncology

Kennewick, Washington, United States

Site Status

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Site Status

Puget Sound Cancer Center - Seattle

Seattle, Washington, United States

Site Status

Cancer Care Northwest-South

Spokane, Washington, United States

Site Status

Rockwood Clinic Cancer Treatment Center

Spokane, Washington, United States

Site Status

Cancer Care Northwest-Radiation Therapy (XRT)

Spokane, Washington, United States

Site Status

Cancer Care Northwest- Valley - Mission

Spokane, Washington, United States

Site Status

Cancer Care Northwest-North - Holland

Spokane, Washington, United States

Site Status

Evergreen Hematology & Oncology (Farwell)

Spokane, Washington, United States

Site Status

Northwest Cancer Specialists-136th Ave

Vancouver, Washington, United States

Site Status

Northwest Cancer Specialists-134th St.

Vancouver, Washington, United States

Site Status

Yakima Valley Memorial Hospital - North Star Lodge

Yakima, Washington, United States

Site Status

Raleigh Regional Cancer Center

Beckley, West Virginia, United States

Site Status

CAMC Health Education & Research Institute, Inc.

Charleston, West Virginia, United States

Site Status

West Virginia University Hospitals Inc.

Morgantown, West Virginia, United States

Site Status

Camden-Clark Memorial Hospital

Parkersburg, West Virginia, United States

Site Status

Wheeling Hospital

Wheeling, West Virginia, United States

Site Status

Marshfield Clinic Chippewa Falls Center

Chippewa Falls, Wisconsin, United States

Site Status

Marshfield Clinic Regional CA Cntr - Sacred Heart Hospital

Eau Claire, Wisconsin, United States

Site Status

CCOP, St. Vincent Hospital

Green Bay, Wisconsin, United States

Site Status

CCOP, St. Mary's Hospital Medical Center

Green Bay, Wisconsin, United States

Site Status

CCOP - Marshfield Clinic Research Foundation

Marshfield, Wisconsin, United States

Site Status

Aurora Sinai Medical Center

Milwaukee, Wisconsin, United States

Site Status

Froedtert Hospital

Milwaukee, Wisconsin, United States

Site Status

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

Marshfield Clinic Minocqua Center

Minocqua, Wisconsin, United States

Site Status

Vince Lombardi Cancer Clinic - Oshkosh

Oshkosh, Wisconsin, United States

Site Status

Marshfield Clinic at James Beck Cancer Center

Rhinelander, Wisconsin, United States

Site Status

Marshfield Clinic Rice Lake Center

Rice Lake, Wisconsin, United States

Site Status

Marshfield Clinic Cancer Care at St. Michael's Hospital

Stevens Point, Wisconsin, United States

Site Status

Aspirus Regional Cancer Center

Wausau, Wisconsin, United States

Site Status

Aurora Women's Pavilion of Aurora West Allis Medical Center

West Allis, Wisconsin, United States

Site Status

CCOP Marshfield Clinic - Weston Center

Weston, Wisconsin, United States

Site Status

Marshfield Clinic Wisconsin Rapids Center

Wisconsin Rapids, Wisconsin, United States

Site Status

Bon Secours Hospital

Cork, CK, Ireland

Site Status

Letterkenny General Hospital

Letterkenny, DL, Ireland

Site Status

Mater Private Hospital

Dublin, DN, Ireland

Site Status

Beaumont Hospital

Dublin, , Ireland

Site Status

St. Vincent's University Hospital

Dublin, , Ireland

Site Status

Mater Misericordiae

Dublin, , Ireland

Site Status

St James' Hospital

Dublin, , Ireland

Site Status

St. James' Hospital

Dublin, , Ireland

Site Status

University College Hospital

Galway, , Ireland

Site Status

Sligo General Hospital

Sligo, , Ireland

Site Status

Waterford Regional Hospital

Waterford, , Ireland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Ireland

References

Explore related publications, articles, or registry entries linked to this study.

Geyer CE Jr, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, Hopkins JO, O'Shaughnessy JA, Rastogi P, Puhalla SL, Hilton CJ, Dang CT, Gomez HL, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Colangelo LH, Swain SM, Mamounas EP, Wolmark N. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). J Clin Oncol. 2024 Apr 20;42(12):1344-1349. doi: 10.1200/JCO.23.01428. Epub 2024 Feb 9.

Reference Type DERIVED
PMID: 38335467 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

USOR 07132

Identifier Type: -

Identifier Source: secondary_id

NSABP B-46-I

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.